ImmuPharma (LON:IMM) Trading 32% Higher - What's Next?

Key Points

• ImmuPharma's shares surged 32% on Monday, reaching as high as GBX 19.35 ($0.26) with a significant trading volume of over 34 million shares, indicating a 316% increase compared to the average session volume.
• The company reported a quarterly earnings per share of GBX (0.38) and has a substantial market capitalization of £89.23 million, despite a negative return on equity of 131.41%.
• ImmuPharma specializes in discovering and developing peptide-based therapeutics, including its lead program Lupuzor™, aimed at treating autoimmune diseases like Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded up 32% on Monday . The stock traded as high as GBX 19.35 ($0.26) and last traded at GBX 18.45 ($0.25). 34,441,395 shares were traded during mid-day trading, an increase of 316% from the average session volume of 8,271,696 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Trading Up 27.7%

The firm has a market capitalization of £89.23 million, a P/E ratio of -2,006.18 and a beta of 1.53. The company has a 50 day simple moving average of GBX 3.12 and a two-hundred day simple moving average of GBX 2.91.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, sell-side analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.